(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.38% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Bioventus's revenue in 2026 is $576,300,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $51,074,838,245, with the lowest BVS revenue forecast at $49,492,689,417, and the highest BVS revenue forecast at $53,162,372,522. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,561,580,171, with the lowest BVS revenue forecast at $52,621,902,463, and the highest BVS revenue forecast at $57,635,660,259.
In 2028, BVS is forecast to generate $57,937,220,832 in revenue, with the lowest revenue forecast at $55,958,281,776 and the highest revenue forecast at $60,561,883,777.